• Explore /
  • Poster
  • / RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A real-world retrospective study.

RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A real-world retrospective study.

Abstract Poster

Authors

null

Haoyang Liu

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

Haoyang Liu , Junru Chen , Haolin Liu , Qiyu Zhu , Banghua Liao , Zhenhua Liu , Pengfei Shen , Hao Zeng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 644)

DOI

10.1200/JCO.2024.42.4_suppl.644

Abstract #

644

Poster Bd #

J8

Abstract Disclosures

Similar Posters

First Author: Zongren Wang

First Author: Zhiyong Li

Poster

2022 ASCO Genitourinary Cancers Symposium

Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.

Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.

First Author: Ian Mitchell McElree

First Author: Michiel Simon Van Der Heijden